Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Silence Therapeutics PLC Sponsored ADR (SLN) had Return on Equity of -25.31% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$0.14M |
|
$-28.53M |
|
$0.05M |
|
$0.09M |
|
$28.55M |
|
$-28.41M |
|
$-0.12M |
|
$-28.53M |
|
$-28.53M |
|
$-28.53M |
|
$-28.53M |
|
$-28.53M |
|
$-28.53M |
|
$-28.41M |
|
$-28.27M |
|
47.23M |
|
47.23M |
|
$-0.60 |
|
$-0.60 |
|
| Balance Sheet Financials | |
$169.79M |
|
$1.69M |
|
$15.51M |
|
$185.30M |
|
$19.26M |
|
-- |
|
$53.29M |
|
$72.56M |
|
$112.74M |
|
$102.65M |
|
$112.74M |
|
47.23M |
|
| Cash Flow Statement Financials | |
$-12.31M |
|
$-44.38M |
|
$0.01M |
|
$121.33M |
|
$64.89M |
|
$-56.44M |
|
$3.54M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.81 |
|
-- |
|
-- |
|
-- |
|
-- |
|
61.97% |
|
-20006.34% |
|
-20006.34% |
|
-- |
|
-20091.55% |
|
-20091.55% |
|
$-12.31M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.01 |
|
0.01M |
|
|
Return on Equity |
-25.31% |
-27.79% |
|
-15.40% |
|
-25.31% |
|
$2.39 |
|
$-0.26 |
|
$-0.26 |
|